Effect of Nigella Sativa on Blood Lipids as an add-on Therapy in Atorvastatin Treated Hyperlipidaemic Patients. A Randomized Controlled Trial
This study will be 8 weeks randomized, double-blind, placebo-controlled trail to assess the effect of Nigella Sativa in 84 Hyperlipidaemic patients. Participants will be assessed at baseline and after 8 weeks of intervention. Subjects will be randomized to receive either Nigella Sativa 500 mg capsule daily or placebo capsule identical to Nigella Sativa twice daily for 8 weeks. Evaluation of lipid profile, SGPT, S.Creatinine will be before and after 8 weeks of intervention. Nigella Sativa related adverse events will be identified. Study outcome will establish safety and efficacy of Nigella Sativa in atorvastatin treated hyperlipidaemic patients
• Newly diagnosed hyperlipidaemic patient.
• Both male and female
• Hyperlipidemic patients suffering from ischemic heart disease, diabetes mellitus, hypertension
• Diagnostic criteria for dyslipidemic patients
‣ Total cholesterol 200mg/dl
⁃ LDL-C 140mg/dl
⁃ Triglyceride 150mg/dl
⁃ HDL \<40mg/dl